Results 251 to 260 of about 21,560 (287)

Leveraging the ADAM10 prodomain for selective inhibition to enhance recovery after myocardial infarction

British Journal of Pharmacology, EarlyView.
Background and Purpose Inflammation plays a crucial role in the development and progression of numerous acute and chronic diseases such as myocardial infarction (MI) and heart failure. Targeting ADAM proteases, particularly ADAM10, holds promise for fine‐tuning inflammatory responses.
Erik Klapproth, Johanna Marks, Patrick Diaba‐Nuhoho, Sören Grell, Paul Leubauer, Susanne Kämmerer, Johannes R. Soltwedel, Fred Rasmussen, Felix Mejia, Marcia L. Moss, Christopher Prince, Peter Mirtschink, Ben Wielockx, Paul Saftig, Michael Wagner, Kristina Lorenz, Ali El‐Armouche   +16 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Comparative analysis of furosemide and torsemide efficacy in 24 hours of acute heart failure admission. [PDF]

Front Pharmacol
Małek-Elikowska M, Szyszka A, Fedorowicz J, Dankowski R, Szymańska C, Baszko A.   +5 more
europepmc   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, EarlyView.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Head-to-Head in Heart Failure: Comparative Insights on Empagliflozin and Dapagliflozin. [PDF]

Biomedicines
Cozma D, Văcărescu C, Stoicescu C.
europepmc   +1 more source

Correction to ‘Natriuretic peptides and C‐reactive protein in in heart failure and malnutrition: A systematic review and meta‐analysis’

ESC Heart Failure, Volume 12, Issue 2, Page 1524-1524, April 2025.
wiley   +1 more source

Songorine inhibits mitophagy in chronic heart failure via the TBC1D15/Fis1/Rab7A pathway

British Journal of Pharmacology, EarlyView.
Abstract Background and purpose Songorine (SGR) is an alkaloid extracted from Aconitum carichaelii Debx. and has a demonstrated role in cardiac dysfunction. Chronic heart failure (CHF) is a severe clinical syndrome leading to functional impairment and death, primarily due to the deterioration of energy metabolism in cardiomyocytes. However, the precise
Wenxiu Liu, Xingju Zou, Yang Zheng, Chen Sun, Cheng Peng   +4 more
wiley   +1 more source

Activation of the alternative complement pathway and its relevance for sodium retention in experimental nephrotic syndrome. [PDF]

Pflugers Arch
Essigke D, Kalo MZ, Kong L, Wörn M, Saad MK, Omage K, Bohnert BN, Birkenfeld AL, Atkinson JP, Wu X, Artunc F.   +10 more
europepmc   +1 more source

Pharmacological inhibition of hydroxysteroid 11‐beta dehydrogenase type 1 (11‐βHSD1) after myocardial infarction preserves cardiac function in a translational mini‐pig model

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Plasma glucocorticoids increase acutely after MI, thereafter tissue levels are amplified selectively within cells expressing 11‐ßhydroxysteroid dehydrogenase type 1 (11‐ßHSD1) that regenerates active glucocorticoids from circulating metabolites.
Sara Al Disi, Raimondo Ascione, Shazia Khan, Thomas Johnson, Eva Sammut, Vito Domenico Bruno, Daniel Baz Lopez, Carol‐Anne James, Joanna Simpson, Natalie Z. Homer, Michael Millar, Trisha Singh, Alex von Kreigsheim, Nick L. Mills, Brian R. Walker, Ruth Andrew, Scott P. Webster, Andrew Whittaker, Adrian Freeman, Gillian A. Gray   +19 more
wiley   +1 more source